Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | FADS1 | O60427 | 4/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17744881 | 0.89 | FADS1 (0.72) | P2RX1ALDH1A1FADS1PTGS1MEN1 | |
| SCHEMBL9810110 | 0.84 | ALDH1A1 (0.72) | P2RX1ALDH1A1FADS1PTGS1MAPT | |
| SCHEMBL31424193 | 0.83 | MEN1 (0.72) | P2RX1ALDH1A1FADS1PTGS1MAPT | |
| SCHEMBL8485797 | 0.83 | FADS1 (0.65) | P2RX1ALDH1A1FADS1PTGS1MEN1 | |
| SCHEMBL259352 | 0.83 | MEN1 (0.72) | P2RX1ALDH1A1FADS1PTGS1MAPT | |
| SCHEMBL5668126 | 0.83 | FADS1 (0.65) | P2RX1ALDH1A1FADS1PTGS1MEN1 | |
| SCHEMBL2700843 | 0.83 | P2RX1 (1.00) | P2RX1ALDH1A1HTTFADS1MAPT | |
| SCHEMBL7820408 | 0.83 | P2RX1 (0.72) | P2RX1ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL30339241 | 0.82 | NPC1 (0.70) | P2RX1ALDH1A1HTTFADS1PTGS1 | |
| SCHEMBL1011053 | 0.82 | NPC1 (0.70) | P2RX1ALDH1A1HTTFADS1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103130696-B | Anthranilamide compound as well as preparation method and application thereof | UNIV SHANDONG | 2014-06-11 | — | — | CN | claimed |
| CN-103130696-B | Anthranilamide compound as well as preparation method and application thereof | UNIV SHANDONG | 2014-06-11 | — | — | CN | disclosed |
| CN-103130696-A | Anthranilamide compound as well as preparation method and application thereof | UNIV SHANDONG | 2013-06-05 | — | — | CN | disclosed |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | P2RX1 1241/4885ALDH1A1 2918/4885HTT 1712/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | P2RX1 983/4885ALDH1A1 3070/4885HTT 1263/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | P2RX1 1269/4885ALDH1A1 3031/4885HTT 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.